Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Mario Negri Institute for Pharmacological Research |
---|---|
Information provided by: | Mario Negri Institute for Pharmacological Research |
ClinicalTrials.gov Identifier: | NCT00157521 |
Pre-eclampsia is a disorder unique to pregnancy affecting both the mother and the fetus. Hypertension, proteinuria and edema are the most common and well-known maternal clinical symptoms. The incidence is approximately 6-8%. Pre-eclampsia is one of the leading causes of maternal and fetal mortality and morbidity associated with pregnancy throughout the world. The pathophysiology is unknown. At present, the most effective treatment is immediate delivery. The researchers' studies contributed to the demonstration that the vasodilator nitric oxide (NO) is important for correct placentation and that less nitric oxide (NO)- dependent vasodilation and an excess formation of reactive oxygen species explain poor placenta perfusion in pre-eclampsia. This reduced NO activity and increased oxidative stress in pre-eclamptic placenta is related to low bioavailability of L-arginine, the NO precursor.
In this pilot study the researchers want to evaluate whether the administration of L-arginine to women with a clinical diagnosis of preeclampsia might restore physiological NO production in the placenta and ameliorate the pregnancy outcome.
Condition | Intervention | Phase |
---|---|---|
Pre-Eclampsia |
Drug: L-arginine |
Phase III |
Study Type: | Interventional |
Study Design: | Educational/Counseling/Training, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomized, Pilot Study to Explore Whether Enhancing L-Arginine Bioavailability by Oral Supplementation Increases NO Production and Prevents Peroxynitrite Generation in the Pre-Eclamptic Placenta |
Estimated Enrollment: | 30 |
Study Start Date: | September 2002 |
Estimated Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Pre-eclamptic women
Normotensive pregnant women
Exclusion Criteria:
Italy | |
Obstetrics and Ginecology Division | |
Brescia, Italy, 25100 | |
Hospital "Ospedali Riuniti", Unit of Obstetrics and Ginecology | |
Bergamo, Italy, 24128 |
Principal Investigator: | Piero Ruggenenti, MD | Mario Negri Institute |
Study ID Numbers: | L-ARG |
Study First Received: | September 8, 2005 |
Last Updated: | December 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00157521 History of Changes |
Health Authority: | Italy: Ministry of Health |
Hypertension, Pregnancy-Induced Pregnancy Complications Eclampsia |
Pre-Eclampsia Preeclampsia Hypertension |
Hypertension, Pregnancy-Induced Pregnancy Complications Eclampsia Pre-Eclampsia |